Status:
RECRUITING
Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor
Lead Sponsor:
Osijek University Hospital
Conditions:
Cognitive Decline
Urinary Bladder Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. One of the procedures in patients with bladder tumors is transurethral resection of the...
Detailed Description
Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. It is the most common malignant disease of the urinary system. One of the procedures in...
Eligibility Criteria
Inclusion
- adult patients from 18-80 years,
- elective operations of tumor bladder cancer (TUR),
- patients can communicate,
- patients who can sign the information consent and questionnaires
Exclusion
- patients under the age of 18,
- patients above 80 years,
- patients who are unable to communicate
- patients who do not understand informed consent for the research,
- patients who are unable to write
- emergency surgery,
- patients with proven hypersensitivity to some of the drugs used in the study
- patients in a state of shock, septic, or hemorrhagic patients with neurodevelopmental disorders
Key Trial Info
Start Date :
November 28 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT07165236
Start Date
November 28 2024
End Date
October 1 2029
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osijek UH
Osijek, Croatia, Croatia, 31000